<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364356">
  <stage>Registered</stage>
  <submitdate>9/10/2013</submitdate>
  <approvaldate>12/11/2013</approvaldate>
  <actrnumber>ACTRN12613001234707</actrnumber>
  <trial_identification>
    <studytitle>A randomised controlled trial comparing daily (400 international units) and single bolus dosing (50,000 international units) of vitamin D in healthy breastfed infants of vitamin D deficient mothers.</studytitle>
    <scientifictitle>A randomised controlled trial evaluating the efficacy and safety of single bolus (50,000 international units) versus daily (400 international units) dosing of vitamin D in healthy breastfed infants of vitamin D deficient mothers.</scientifictitle>
    <utrn>Nil</utrn>
    <trialacronym />
    <secondaryid>nil</secondaryid>
    <secondaryid>The VINE study</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>vitamin D deficiency in healthy term babies born the mothers who are vitamin D deficient</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>arm 1: 400IU vitamin D orally - Pentavite (Bayer Health) given daily for 4 months from birth
arm 2: 50,000 vitamin D orally - Given as pharmacy formulated Cholecalciferol as a single dose at birth only.
Patients will be followed up at 6-8 days of age and 3-4 months of age for biochemical markers of vitamin D deficiency (vitamin D and calcium levels) and reviewed for compliance, growth, side effects and signs of vitamin d deficiency</interventions>
    <comparator>arm 1 = active standard treatment
400IU vitamin D given orally on a daily basis for 4 months</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>25 OH vitamin D levels. This will be assessed by immunoassay on a Liason analyser.</outcome>
      <timepoint>at birth using cord blood.
at 6-8 days using blood collected from patients
at 3-4 months using blood collected from patients</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Total Calcium and albumin levels as a measure of safety of vitamin D supplementation. These parameters will be measured by routine laboratory methods on a Beckman auto analyser.
</outcome>
      <timepoint>At birth
at 6-8 days
at 3-4 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>clinical parameters of vitamin D deficiency by assessment of growth parameters (head circumference, weight and length) and clinical signs of vitamin D deficiency such as craniotabes, widened anterior fontanelle, limb deformities, rachitic rosary.</outcome>
      <timepoint>At birth
at 6-8 days of age
at 3-4 months of age</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>measurement of compliance to vitamin D supplementation. This will be achieved by reconciling the remaining volumes of medication with expected volumes as recorded by the clinical trials pharmacy.</outcome>
      <timepoint>at 6-8 days
at 3-4 months on final review</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>term, singleton babies
mothers with vitamin D levels &lt; 50 at &gt; 35 week
intention to breastfeed</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Hours</inclusiveminagetype>
    <inclusivemaxage>5</inclusivemaxage>
    <inclusivemaxagetype>Months</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>intra-uterine growth restriction
pre-existing maternal diabetes, thyroid disorders
Neonates requiring significant resuscitation, CPR and intubation
maternal drug dependence
twin pregnancies</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>antenatal screening for maternal vitamin D levels. consent and recruitment can be in antenatal clinic, birth suite, or pregnancy care centre/pregnancy day stay unit.  Blinded randomisation to occur at birth from opaque sealed envelopes. </concealment>
    <sequence>Block randomisation using a schedule generated by computer software (i.e computer sequence generation)</sequence>
    <masking />
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>The sample size calculation was undertaken using the following assumptions: power = 90%; alpha = 0.05 (2-sided); 55% of patients in the control group (daily dosing vitamin D) having 25 OH vit D levels &gt; 50nmol/L at 4 months of age; and 95% of patients in the intervention group (single bolus group) having 25 OH vit D levels &gt; 50nmol/L at 4 months of age.  Based on these parameters, 28 patients will be needed in each group. To allow for 20% drop-out, we will recruit an extra 4 patients in each. 

The above presumption is based on published reports of 45% non compliance in the daily group and therefore presumed to have suboptimal vitamin D levels. This percentage is a realistic reflection of the high drop out rates and poor compliance seen in the multicultural population at Western Health services.  Theoretically, 100% of patients in the intervention group would be expected to be vitamin D replete, however it is presumed for this study that 95% will be replete to account for a small population who may be poor metabolisers  (absent or impaired 24 hydroxylase enzyme) of vitamin D.
</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>1/07/2013</anticipatedstartdate>
    <actualstartdate>12/08/2013</actualstartdate>
    <anticipatedenddate>2/02/2014</anticipatedenddate>
    <actualenddate>29/11/2013</actualenddate>
    <samplesize>70</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <postcode>3021 - St Albans</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Sunshine Hospital</primarysponsorname>
    <primarysponsoraddress>176 Furlong Rd
St Albans 3021, Victoria</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Department of Paediatrics, Sunshine Hospital</fundingname>
      <fundingaddress>176 Furlong Rd, St Albans 3021, Victoria</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Other Collaborative groups</fundingtype>
      <fundingname>Australian Institute of Musculoskeletal Science</fundingname>
      <fundingaddress>Sunshine Hospital
Western Centre for Health and Research
176 Furlong Rd, St Albans 3021, Victoria</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>Australian Institute MusculoSkeletal Science (AIMSS)
Western Centre for Health and Research 
</sponsorname>
      <sponsoraddress>Sunshine Hospital
176 Furlong Rd
St Albans 3021, Victoria</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr James Doery</othercollaboratorname>
      <othercollaboratoraddress>Monash Medical centre
246 Monash Rd, Clayton 3168 Victoria</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Prof Danny Liew</othercollaboratorname>
      <othercollaboratoraddress>Melbourne Epicentre
University of Melbourne and Melbourne Health
Grattan St, Parkville, 3052 Victoria</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To assess the proportion of  breastfed infants who are vitamin D sufficient (25 OH vit D &gt; 50nmol/L) in the intervention group (bolus vitamin D dosing) versus the standard daily vitamin D dosing. This will be achieved by measurement of 25 OH vit D levels ; a marker of vitamin D status.
This is an open label, single site - hospital based centre
Primary: Proportion of subjects at 4 months of age with 25 OH vit D levels &gt; 50nmol/L.
Secondary: Total calcium as marker of safety, compliance, clinical     
markers of vitamin D deficiency
Recruitment period: May  Feb 2014.  Four month follow up period
 1) 400 IU vitamin D  daily 
 2)  50,000 IU at birth only (bolus)
Sample size of 70 with 28 in each group + drop out rate.
Term breastfed infants born to pregnant women who are found to be vitamin D deficient (25 OH vit D &lt; 50nmol/L) at  35-37 weeks gestation
</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Children Hospital</ethicname>
      <ethicaddress>50 Flemington Rd
Parkville 3052, Victoria</ethicaddress>
      <ethicapprovaldate>28/05/2013</ethicapprovaldate>
      <hrec>33044A</hrec>
      <ethicsubmitdate>8/04/2013</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Julie Huynh</name>
      <address>Sunshine Hospital
176 Furlong Rd
St Albans 3021, Victoria</address>
      <phone>+61 3 8345 1333</phone>
      <fax />
      <email>julie.huynh@wh.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Christine Rodda</name>
      <address>Sunshine Hospital
University of Melbourne
North West Academic Centre
level 3, Rm 5.056
Sunshine Hospital
176 Furlong Rd, St Albans 3021, Victoria</address>
      <phone>+61 3 8395 8161</phone>
      <fax />
      <email>christine.rodda@unimelb.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Julie Huynh</name>
      <address>Sunshine Hospital
176 Furlong Rd
St Albans 3021, Victoria</address>
      <phone>+61 3 8345 1333</phone>
      <fax />
      <email>julie.huynh@wh.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Julie Huynh</name>
      <address>Sunshine Hospital
176 Furlong Rd
St Albans 3021, Victoria</address>
      <phone>+61 3 8345 1333</phone>
      <fax />
      <email>julie.huynh@wh.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>